- Home
- NOTV vs IGC Comparison
NOTV vs IGC Comparison
Compare NOTV & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTV
- IGC
- Stock Information
- Founded
- NOTV 1974
- IGC 2005
- Country
- NOTV United States
- IGC United States
- Employees
- NOTV N/A
- IGC N/A
- Industry
- NOTV Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- NOTV Health Care
- IGC Health Care
- Exchange
- NOTV Nasdaq
- IGC Nasdaq
- Market Cap
- NOTV 46.7M
- IGC 39.8M
- IPO Year
- NOTV 1997
- IGC N/A
- Fundamental
- Price
- NOTV $1.39
- IGC $0.41
- Analyst Decision
- NOTV Strong Buy
- IGC Strong Buy
- Analyst Count
- NOTV 1
- IGC 2
- Target Price
- NOTV $5.00
- IGC $4.00
- AVG Volume (30 Days)
- NOTV 446.2K
- IGC 667.7K
- Earning Date
- NOTV 08-06-2025
- IGC 11-11-2025
- Dividend Yield
- NOTV N/A
- IGC N/A
- EPS Growth
- NOTV N/A
- IGC N/A
- EPS
- NOTV N/A
- IGC N/A
- Revenue
- NOTV $505,299,000.00
- IGC $1,327,000.00
- Revenue This Year
- NOTV $5.64
- IGC $15.26
- Revenue Next Year
- NOTV $5.16
- IGC $3.41
- P/E Ratio
- NOTV N/A
- IGC N/A
- Revenue Growth
- NOTV 0.85
- IGC 24.95
- 52 Week Low
- NOTV $1.15
- IGC $0.25
- 52 Week High
- NOTV $6.48
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- NOTV 42.19
- IGC 50.95
- Support Level
- NOTV $1.41
- IGC $0.39
- Resistance Level
- NOTV $1.57
- IGC $0.43
- Average True Range (ATR)
- NOTV 0.12
- IGC 0.02
- MACD
- NOTV 0.02
- IGC -0.00
- Stochastic Oscillator
- NOTV 31.19
- IGC 37.17
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.